Celon Labs launches emulsion-based drug to treat black fungus in COVID patients
Advertisement
Hyderabad: Hyderabad based specialty biopharmaceutical manufacturer, Celon Laboratories, has recently announced the launch of an alternative drug - Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus.
The drug is set to provide much needed respite to patients reeling under the severe impact of the second wave of COVID-19 and the resultant Black Fungus.
Amphotericin B, is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among COVID-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany — lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation.
Exhaustively developed by Celon's in-house R&D team in a record three weeks, the emulsion- based formulation will provide leading hospitals and COVID-19 treatment centers with increased resources to treat the Black Fungus. Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.
Celon Labs' Managing Director, Mr. M. Nagesh Kumar, spoke of Celon's role during India's second wave of COVID-19: "Celon Labs is deeply committed to supporting the ongoing efforts to combat the Covid-19 pandemic during this deadly second wave and to save as many lives as possible. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying the domestic market soon."
Additionally, the Chairman of Celon, Mr. Hocine Sidi-Said, expressed his gratitude to employees for achieving this important milestone: "I am delighted to see that Celon Labs has mobilized its talents and expertise to swiftly respond to this pressing medical need. I am grateful to the team at Celon Labs who have made the launch of Amphotericin B Emulsion possible."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.